ABSTRACT
Description: Humalog is a fast-acting insulin analogue. It is chemically identical to human insulin, except for an inversion of the natural proline-lysine sequence at positions 28 and 29 of the insulin B chain. It is produced by recombinant DNA technology in Escherichia coli. Its final product presentation is as a solution for injection, containing Zn-insulin lispro crystals, and it is administered subcutaneously. A new formulation consisting of a lesser amount of Humalog dissolved in water and the remainder in suspension with protamine sulphate, or completely in suspension with protamine sulphate, is also available.
